Recently Updated Guidelines
Guidelines for Treatment of Cancer by Type
-
Acute Lymphoblastic Leukemia Version 1.2021
-
B-Cell Lymphomas Version 4.2021
-
Bladder Cancer Version 3.2021
-
Breast Cancer Version 4.2021
-
Central Nervous System Cancers Version 5.2020
-
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Version 4.2021
-
Gestational Trophoblastic Neoplasia Version 2.2021
-
Head and Neck Cancers Version 3.2021
-
Hepatobiliary Cancers Version 2.2021
-
Hodgkin Lymphoma Version 4.2021
-
Kidney Cancer Version 4.2021
-
Melanoma: Uveal Version 1.2021
-
Multiple Myeloma Version 7.2021
-
Myeloproliferative Neoplasms Version 1.2021
-
Neuroendocrine and Adrenal Tumors Version 1.2021
-
Pediatric Hodgkin Lymphoma Version 3.2021
-
Small Cell Lung Cancer Version 3.2021
-
Soft Tissue Sarcoma Version 2.2021
-
Systemic Mastocytosis Version 1.2021
-
Testicular Cancer Version 2.2021
-
Thyroid Carcinoma Version 1.2021
-
Uterine Neoplasms Version 2.2021
-
Vulvar Cancer Version 3.2021
-
NCCN Guidelines with Evidence Blocks - Acute Lymphoblastic Leukemia Version 1.2021
-
NCCN Guidelines with Evidence Blocks - B-Cell Lymphomas Version 4.2021
-
NCCN Guidelines with Evidence Blocks - Bladder Cancer Version 3.2021
-
NCCN Guidelines with Evidence Blocks - Breast Cancer Version 4.2021
-
NCCN Guidelines with Evidence Blocks - Central Nervous System Cancers Version 5.2020
-
NCCN Guidelines with Evidence Blocks - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Version 4.2021
-
NCCN Guidelines with Evidence Blocks - Gestational Trophoblastic Neoplasia Version 2.2021
-
NCCN Guidelines with Evidence Blocks - Head and Neck Cancers Version 3.2021
-
NCCN Guidelines with Evidence Blocks - Hepatobiliary Cancers Version 2.2021
-
NCCN Guidelines with Evidence Blocks - Hodgkin Lymphoma Version 4.2021
-
NCCN Guidelines with Evidence Blocks - Kidney Cancer Version 4.2021
-
NCCN Guidelines with Evidence Blocks - Melanoma: Uveal Version 1.2021
-
NCCN Guidelines with Evidence Blocks - Multiple Myeloma Version 7.2021
-
NCCN Guidelines with Evidence Blocks - Myeloproliferative Neoplasms Version 1.2021
-
NCCN Guidelines with Evidence Blocks - Neuroendocrine and Adrenal Tumors Version 1.2021
-
NCCN Guidelines with Evidence Blocks - Pediatric Hodgkin Lymphoma Version 3.2021
-
NCCN Guidelines with Evidence Blocks - Small Cell Lung Cancer Version 3.2021
-
NCCN Guidelines with Evidence Blocks - Soft Tissue Sarcoma Version 2.2021
-
NCCN Guidelines with Evidence Blocks - Systemic Mastocytosis Version 1.2021
-
NCCN Guidelines with Evidence Blocks - Testicular Cancer Version 2.2021
-
NCCN Guidelines with Evidence Blocks - Thyroid Carcinoma Version 1.2021
-
NCCN Guidelines with Evidence Blocks - Uterine Neoplasms Version 2.2021
-
NCCN Guidelines with Evidence Blocks - Vulvar Cancer Version 3.2021
Guidelines for Detection, Prevention, & Risk Reduction
-
Breast Cancer Risk Reduction Version 1.2021
-
Breast Cancer Screening and Diagnosis Version 1.2021
-
Colorectal Cancer Screening Version 2.2021
-
Genetic/Familial High-Risk Assessment: Colorectal Version 1.2021
Guidelines for Supportive Care
-
Hematopoietic Cell Transplantation Version 2.2021
-
Hematopoietic Growth Factors Version 3.2021
-
Management of Immunotherapy-Related Toxicities Version 3.2021
Guidelines for Specific Populations
-
Cancer in People with HIV Version 2.2021